Kiora Pharmaceuticals (KPRX) Expected to Post Quarterly Earnings on Friday

Kiora Pharmaceuticals (NASDAQ:KPRX) is projected to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Kiora Pharmaceuticals to announce earnings of ($0.38) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Kiora Pharmaceuticals (NASDAQ:KPRX) last posted its earnings results on Friday, August 7th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.13.

Kiora Pharmaceuticals Stock Performance

Shares of KPRX opened at $1.73 on Wednesday. Kiora Pharmaceuticals has a twelve month low of $1.55 and a twelve month high of $2.91. The company has a 50 day moving average of $2.46 and a two-hundred day moving average of $2.40.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Kiora Pharmaceuticals in a research note on Monday, October 12th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, Kiora Pharmaceuticals has a consensus rating of “Sell”.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders.

Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.